Boyu Hu

1.1k total citations
34 papers, 210 citations indexed

About

Boyu Hu is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Boyu Hu has authored 34 papers receiving a total of 210 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 17 papers in Oncology and 15 papers in Genetics. Recurrent topics in Boyu Hu's work include Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (15 papers) and CAR-T cell therapy research (8 papers). Boyu Hu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (15 papers) and CAR-T cell therapy research (8 papers). Boyu Hu collaborates with scholars based in United States, Australia and Germany. Boyu Hu's co-authors include Yasuhiro Oki, Zihua Hu, James F. Collins, Deborah M. Stephens, Harsh Shah, Randa Tao, Jonathan Chipman, Lindsey Fitzgerald, John C. Byrd and P. Joy Ho and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Boyu Hu

29 papers receiving 209 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Boyu Hu United States 9 122 99 64 52 44 34 210
Timothy Voorhees United States 8 152 1.2× 80 0.8× 53 0.8× 55 1.1× 20 0.5× 37 240
Paolo Strati United States 6 162 1.3× 71 0.7× 40 0.6× 54 1.0× 56 1.3× 21 223
Remus Vezan United States 9 161 1.3× 67 0.7× 95 1.5× 35 0.7× 32 0.7× 17 238
Ahmed Galal United States 6 113 0.9× 77 0.8× 99 1.5× 35 0.7× 39 0.9× 13 234
Harry Miao United States 9 104 0.9× 64 0.6× 28 0.4× 16 0.3× 16 0.4× 33 149
Monalisa Ghosh United States 9 170 1.4× 46 0.5× 87 1.4× 63 1.2× 17 0.4× 45 308
Jasmine M. Zain United States 11 162 1.3× 156 1.6× 57 0.9× 112 2.2× 30 0.7× 25 305
Evangelia Stalika Greece 9 42 0.3× 99 1.0× 24 0.4× 109 2.1× 137 3.1× 35 220
Stefano Vergani United States 9 38 0.3× 32 0.3× 59 0.9× 125 2.4× 55 1.3× 19 202
Matteo Doglio Italy 8 150 1.2× 17 0.2× 50 0.8× 116 2.2× 22 0.5× 19 245

Countries citing papers authored by Boyu Hu

Since Specialization
Citations

This map shows the geographic impact of Boyu Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boyu Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boyu Hu more than expected).

Fields of papers citing papers by Boyu Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boyu Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boyu Hu. The network helps show where Boyu Hu may publish in the future.

Co-authorship network of co-authors of Boyu Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Boyu Hu. A scholar is included among the top collaborators of Boyu Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boyu Hu. Boyu Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wada, David A., et al.. (2024). Ultra‐low dose radiation therapy for primary cutaneous indolent B‐cell lymphomas. SHILAP Revista de lepidopterología. 3(4). 1190–1194. 1 indexed citations
3.
Hu, Boyu, Loretta J. Nastoupil, Houston Holmes, et al.. (2024). A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.. Journal of Clinical Oncology. 42(16_suppl). 7025–7025. 9 indexed citations
4.
5.
6.
Bock, Allison M., Joshua J. Horns, Harsh Shah, et al.. (2024). Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation. Blood. 144(Supplement 1). 1864–1864.
7.
Shah, Harsh, Lindsey Fitzgerald, Randa Tao, et al.. (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clinical Lymphoma Myeloma & Leukemia. 24(2). 94–104.e6. 1 indexed citations
8.
9.
Stephens, Deborah M., Kenneth M. Boucher, David A. Wada, et al.. (2023). YIA23-004: Non-Melanoma Skin Cancer (NMSC) in Patients With Chronic Lymphocytic Leukemia (CLL): Biology and Prevention. Journal of the National Comprehensive Cancer Network. 21(3.5). YIA23–4.
10.
Stephens, Deborah M., Ying Huang, Amy S. Ruppert, et al.. (2022). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clinical Cancer Research. 28(15). 3242–3247. 20 indexed citations
11.
Chipman, Jonathan, Matthew Parsons, Randa Tao, et al.. (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Advances in Radiation Oncology. 7(6). 101035–101035. 4 indexed citations
12.
Shah, Harsh, et al.. (2022). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic lymphoma.. Journal of Clinical Oncology. 40(16_suppl). 7508–7508. 2 indexed citations
13.
Shah, Harsh, et al.. (2022). Survival outcomes in patients with chronic lymphocytic leukemia treated at academic centers.. Journal of Clinical Oncology. 40(16_suppl). 7544–7544. 2 indexed citations
14.
Hu, Boyu, Jay Patel, Randa Tao, et al.. (2022). Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation. Journal of the National Comprehensive Cancer Network. 20(6). 618–621. 10 indexed citations
15.
Shah, Harsh, et al.. (2021). Treatment Outcomes of Consolidative Radiation in Extranodal Early-Stage Diffuse Large B-Cell Lymphoma. Blood. 138(Supplement 1). 49–49. 1 indexed citations
16.
Feusier, Julie, Brian J. Avery, Justin A. Williams, et al.. (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. PubMed. 5. 189–199.
17.
Dave, Hema, Melanie Grant, Maja Stanojević, et al.. (2021). Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma. Blood Advances. 6(2). 473–485. 13 indexed citations
18.
Stephens, Deborah M., Ying Huang, Akwasi Agyeman, et al.. (2019). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study. Blood. 134(Supplement_1). 4310–4310. 4 indexed citations
19.
Hu, Boyu & Yasuhiro Oki. (2018). Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. Frontiers in Oncology. 8. 139–139. 34 indexed citations
20.
Hu, Zihua, Boyu Hu, & James F. Collins. (2007). Prediction of synergistic transcription factors by function conservation. Genome biology. 8(12). R257–R257. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy Voorhees Breakdown of academic impact, for papers by Paolo Strati Breakdown of academic impact, for papers by Remus Vezan Breakdown of academic impact, for papers by Ahmed Galal Breakdown of academic impact, for papers by Harry Miao Breakdown of academic impact, for papers by Monalisa Ghosh Breakdown of academic impact, for papers by Jasmine M. Zain Breakdown of academic impact, for papers by Evangelia Stalika Breakdown of academic impact, for papers by Stefano Vergani Breakdown of academic impact, for papers by Matteo Doglio
Rankless by CCL
2026